||B7-2 (CD86) signaling through CTLA4(CD152) has been shown to inhibit T cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host"s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer.
||The CTLA4[Biotinylated]:B7-2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-2 interaction. The key to this kit is the high sensitivity of detection of biotin-labeled CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, B7-2 is coated on a 96-well plate. Next, CTLA4-biotin is incubated with B7-2 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.
||This kit is useful for screening for inhibitors of CTLA4 binding to B7-2.
||Stable at least 6 months from date of receipt, when stored as directed. Kit components require different storage conditions. Be sure to store each component at the proper temperature upon arrival
||CTLA4 (CD152), Fc fusion, Biotin-labeled: 3 µg; -80°C B7-2 (CD86), Fc fusion: 10 µg; -80°C Streptavidin-HRP: 15 µl; +4°C 3x CTLA4 Assay Buffer: 50 ml; -20°C Blocking Buffer: 50 ml; +4°C HRP chemiluminescent substrate A (transparent bottle): 6 ml; +4°C HRP chemiluminescent substrate B (brown bottle): 6 ml; +4°C White 96-well microplate: 1; +4°C